RLAY - Relay Therapeutics, Inc.

13.03
-1.920   -14.735%

Share volume: 6,614,816
Last Updated: 04-28-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: 0.20%

PREVIOUS CLOSE
CHG
CHG%
$14.95
-1.92
-0.13%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
37%
Profitability 43%
Dept financing 20%
Liquidity 58%
Performance 30%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-13.88%
1 Month
39.36%
3 Months
69.00%
6 Months
78.25%
1 Year
320.32%
2 Year
97.72%
Key data
Stock price
$13.03
P/E Ratio 
0.00
DAY RANGE
$12.81 - $15.07
EPS 
-$1.62
52 WEEK RANGE
$2.67 - $17.32
52 WEEK CHANGE
$291.29
MARKET CAP 
1.466 B
YIELD 
N/A
SHARES OUTSTANDING 
178.726 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-01-2025
BETA 
2.30
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$3,315,150
AVERAGE 30 VOLUME 
$3,666,426
Company detail
CEO: Sanjiv K. Patel
Region: US
Website: relaytx.com
Employees: 330
IPO year: 2020
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Relay Therapeutics, Inc. engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial.

Recent news